Trial Profile

Safety and Effectiveness of Regorafenib in Routine Clinical Practice Settings

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 25 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Regorafenib (Primary)
Indications Colorectal cancer
Focus Adverse reactions
Acronyms Correlate
Sponsors Bayer

Most Recent Events

25 Oct 2021 Results (n=128) of an analysis assessing safety and effectiveness of regorafenib in Taiwanese subpopulation from this trial published in the Journal of the Formosan Medical Association
04 Nov 2019 Results (n=1037) assessing safety and effectiveness of in patients with metastatic colorectal cancer published in the European Journal of Cancer
19 Jan 2019 Results presented at the 2019 Gastrointestinal Cancers Symposium

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com